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Abstract
Introduction: Ageing may cause an increase in parathormone (PTH) secretion and, subsequently, increased bone resorption and osteopo-
rosis. In recent years two subfractions of PTH have been discovered: cyclase-activating (1–84, CAP) and cyclase-inhibiting (7–84, CIP) PTH.
It is not known however, whether these may play a role in the pathogenesis of bone loss in elderly subjects.
Material and methods: Sixty elderly women were examined, of whom 29 had a T-score of the ultradistal radius < –2.5 (median age 75
[70–80] years, BMI 25 [20.6–33.8] kg/m2, creatinine clearance 59.9 [39.2–94.9] ml/min/1.73m2, serum Ca 2.4 [2.2–2.6] mmol/l), while 31 had
a T-score > –2.5 (median age 73 [70–86] years, BMI 26.2 [18.8–32.5] kg/m2, creatinine clearance 54.8 [23–119.2] ml/min/1.73m2, serum Ca 2.4
[2.2–2.6] mmol/l). Median bone mineral density (BMD) (DXA, Lunar) of the ultradistal radius was 0.263 (0.195–0.449) g/cm2 and
0.326 (0.236–0.448) g/cm2 (p < 0.0001), with a median T-score of –3.48 and –1.4, respectively. Each patient with a serum concentration of
1–84 and 7–84 PTH was assessed.
Results: Patients with low BMD did not differ from those with higher BMD with regard to serum iPTH (16 [6–51] vs. 11.5 [7–35] pg/ml,
p = 0.066) and CIP (6 [1–14] vs. 4.5 [2–13] pg/ml) concentrations. However, serum CAP concentrations (10.5 [4–41] vs. 6 [4–22] pg/ml,
p < 0.05) and CAP/CIP ratios (2.0 [0.71–11] vs. 1.25 [0.5–4.2], p < 0.05) were significantly higher in the low BMD group.
Conclusion: In elderly women increased serum CAP concentrations and CAP/CIP ratios are associated with low BMD of the trabecular
bone. Pol J Endocrinol 2008; 59 (6): 471–476)
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Streszczenie
Wstęp: Z wiekiem stężenie parathormonu (PTH) może się zwiekszać. Konsekwencją tego jest zwiększona resorpcja kości i osteoporoza.
W ostatnich latach odkryto dwie frakcje PTH — aktywującą (1–84, CAP) i hamującą (7–84, CIP) cyklazę. Nie jest jasne, czy te frakcje
odgrywają rolę w patogenezie utraty masy kostnej u osób starszych.
Materiał i metody: Do badania włączono 60 kobiet. U 29 z nich T-score ultradystalnej części kości promieniowej wynosiło < –2.5
(śr. wieku 75 [70–80] lat, BMI 25 [20,6–33,8] kg/m2, klirens kreatyniny 59,9 [39,2–94,9] ml/min/1,73m2, stężenie Ca w surowicy 2,4 [2,2–2,6]
mmol/l), a u 31 kobiet T-score > – 2,5 (śr. wieku 73 [70–86] lat, BMI 26,2 [18,8–32.5] kg/m2, klirens kreatyniny 54,8 [23–119,2] ml/min/1,73m2,
stężenie Ca w surowicy 2,4 [2,2–2,6] mmol/l). Gęstość mineralna kości (BMD) (DXA, Lunar) ultradystalnej części kości promieniowej
wynosiła odpwiednio 0,263 (0,195–0,449) g/cm2 i 0,326 (0,236–0,448) g/cm2 (p < 0,0001), z medianą T-score odpowiednio –3,48 i –1,4.
U każdej chorej oznaczono 1–84 i 7–84 PTH.
Wyniki: Chore z niskim BMD kości promieniowej nie różniły się od tych z wyższym BMD stężeniem iPTH (16 [6–51] vs. 11,5 [7–35] pg/ml,
p = 0,066) ani CIP (6 [1–14] vs. 4,5 [2–13] pg/ml) w surowicy. Jednakże stężenie CAP w surowicy (10,5 [4–41] vs. 6 [4–22] pg/ml, p < 0,05)
oraz iloraz CAP/CIP (2,0 [0,71–11] vs. 1,25 [0,5–4,2], p < 0,05) były znamiennie większe u kobiet z niskim BMD.
Wnisek: U starszych kobiet zwiększone stężenie CAP w surowicy i zwiększony iloraz CAP/CIP stowarzyszone są z niską gęstością mine-
ralną kości beleczkowej. (Endokrynol Pol 2008; 59 (6): 471–476)
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The regulation of bone metabolism is a very complica-
ted process, in which many anabolic and catabolic fac-
tors may be involved, including parathormone (PTH),
calcitonin and 1.25(OH)2 vitamin D3. A predominance
of catabolic over anabolic factors leads to increased bone
resorption and osteoporosis. There are two main types
of primary osteoporosis, postmenopausal and senile.
The latter affects subjects older than 65–70 years. A role
is played in the pathogenesis of senile osteoporosis by
factors such as low peak bone mass, calcium and vita-
min D insufficiency and increased PTH secretion [1–4].
PTH acts on the bone in a complex way. It is known
that PTH causes an increase in the number and activity
of osteoclasts, resulting in bone resorption and loss of
calcium from the bone. However, this effect appears to
be indirect, as there are no PTH receptors on the oste-
oclast surfaces, and is mediated by osteoblasts. PTH sti-
mulates the synthesis and secretion of molecules such
as Il-6 or RANK-L, which influence osteoclastogenesis
[5], and decreases apoptosis of osteoclasts [6]. On the
other hand, PTH may, especially during skeleton
growth but also when given in pharmacological doses,
exert a strong anabolic effect on bone [7, 8]. It seems
that this effect is more profound on trabecular bone [9],
although the catabolic effect of PTH, for example when
hypersecreted by the parathyroid glands in hyperpa-
rathyroidism, is shown mainly in cortical bone [10].
These two different actions may depend on the total
amount of PTH secreted as well as on changes in pulsa-
tile PTH secretion [11–13]. Nevertheless, it appears that
in investigating the influence that physiologically se-
creted PTH exerts on the bones, bone mineral density
(BMD) of the trabecular rather than of the cortical bone
should be measured. The ultradistal radius is a measu-
rement site where the bone is composed of the highest
percentage of trabecular bone and the lowest percenta-
ge of cortical bone.
In the last decade it has been discovered that asses-
sed “intact” PTH in fact includes two subfractions: PTH
1–84 and PTH 7–84 [14–16]. The latter molecule acts in
the opposite manner to the former in that it does not
activate adenylate cyclase and does not increase serum
calcium concentration [17]. It is not clear, however,
whether these findings, obtained mainly in vitro, ade-
quately reflect processes taking place in human phy-
siology and pathology. Most of the clinical data publi-
shed about the PTH subfractions, namely CAP (cycla-
se-activating peptide) and CIP (cyclase-inhibiting pep-
tide), are based on patients with chronic kidney disease.
The original research showed that the intensity of bone
turnover in these patients may be dependent on the
CAP/CIP ratio [18], but this was not confirmed [19]. As-
sessment of 1–84 and 7–84 PTH in renal osteodystro-
phy is probably not necessary for every patient but may
be of importance in some cases [20, 21]. It probably of-
fers no advantage over “whole” PTH assessment in pa-
tients with primary hyperparathyroidism [22]. No data
has been published regarding the role of CAP and CIP
in the pathogenesis of osteoporosis. The present study
aimed to assess serum concentrations of CAP and CIP
in elderly women with low trabecular BMD.
Material and methods
Sixty women aged more than 70 years were included
in the study. The protocol was approved by the Bio-
ethical Commission of the Medical University of Sile-
sia, and all the participants signed a form giving their
informed consent.
The criteria for exclusion were as follows: a BMI lo-
wer than 18 or higher than 35 kg/m2, secondary osteopo-
rosis (especially primary or secondary hyperparathyro-
idism with PTH > 65 ng/ml), previous antifracture treat-
ment, any neoplasm, hyper- or hypocalcaemia, chronic
kidney disease with a serum creatinine concentration of
more than 250 µmol/l, chronic hepatic disease indicated
by AlAT and AspAT activity elevated more than thre-
efold, and any other condition which was considered to
be a contra-indication for the study in the opinion of the
investigator. Cigarette smokers were also excluded.
The patients were divided into two groups. The first
group comprised 29 women with an ultradistal radius
T-score of < –2.5, while the second consisted of 31 wo-
men with T-scores ≥ –2.5.
The two groups did not differ with regard to age or
basic anthropometric and biochemical parameters (Ta-
ble I). BMD measurements from other parts of the skele-
ton differed significantly between the groups (Table II).
Blood samples were taken from each patient for the
estimation of serum Ca, P, Na, K, creatinine and PTH sub-
fraction concentrations. Daily excretion of Na, K, Ca, P and
creatinine in the urine was also evaluated. All patients were
advised to stop calcium and vitamin D treatment one week
before urine collection. Creatinine clearance was calcula-
ted using the Cockroft-Gault formula [23].
The Duo PTH IRMA kit (Scantibodies Laboratory
Inc., USA) was used to assess PTH subfraction concen-
trations. This kit allows for “whole” PTH (= 1–84 PTH
= CAP) and “total” PTH (comprises 1–84 and 7–84 frag-
ments) evaluation [24]. All remaining blood and urine
parameters were assessed by routine laboratory me-
thods. Bone densitometry (the dual-energy X-ray me-
thod, DXA) was performed using a LUNAR machine.
The BMD (g/cm2) of the radius, femoral neck and lum-
bar spine were measured and the T-score calculated.
Cortical bone was assessed in the proximal one third of
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the radius shaft (33%) and trabecular bone in the ultra-
distal part of the radius.
Statistical analysis was performed using STATISTI-
CA software. The Mann-Whitney test was used for com-
parison between the two groups, with the Spearman
rank test being used for univariate correlations. The in-
fluence on dependent variables was verified by stepwise
backward regression multivariate analysis.
Table I. Anthropometric and biochemical characteristics of the examined group, divided according to the ultradistal radius
T-score. Creatinine clearance is calculated according to the Cockroft-Gault formula [20]. Values are given as median (range)
Tabela I. Charakterystyka biochemiczna i antropometryczna badanych grup (podział wg wartości T-score dla części
ultradystalnej kości promieniowej). Klirens kreatyniny obliczono według wzoru Cockrofta-Gaulta [20]. Wartości podano
jako medianę, w nawiasach wartości minimalna i maksymalna
Women with T score Women with T score Statistical significance of
< –2.5 SD (group A) ≥ –2.5 SD (group B) difference between A and B
Age (years) 75 (70–80) 73 (70–86) NS
Weight [kg] 64 (48–82) 70 (50–83) NS
Height [cm] 158 (146–169) 160 (148–173) NS
BMI [kg/m2] 25 (20.6–33.8) 26.2 (18.8–32.5) NS
Serum Na [mmol/l] 143 (136–148) 143 (136–151) NS
Serum K [mmol/l] 4.7 (3.7–5.8) 4.5 (3.6–5.9) NS
Serum Ca [mmol/l 2.4 (2.2–2.6) 2.4 (2.2–2.6) NS
Serum P [mmol/l] 1.12 (0.8–1.85) 1.27 (0.82–2.89) NS
Serum creatinine [µmol/l] 88 (50–120) 90 (50–233) NS
Creatinine clearance [ml/min] 59.9 (39.2–94.9) 54.8 (23.0–119.2) NS
24 h Ca excretion [mmol/24 h] 1.8 (0.3–6.0) 2.5 (0.4–4.9) NS
24 h P excretion [mmol/24 h] 18 (6–41) 16 (8–29) NS
24 h creatinine excretion [mmol/24 h] 7 (3.4–16.5) 6.2 (3–10) NS
Table II. Bone mineral density and T-scores in different sites of the skeleton in women with ultradistal radius T-scores lower
than or equal to/higher than –2.5. Median value (range)
Tabela II. Gęstość mineralna kości (BMD) i wartości T-score różnych lokalizacji kostnych w badanych grupach. Wartości
podano jako medianę, w nawiasach wartości minimalna i maksymalna
Women with a T-score Women with a T-score Statistical significance of
< –2.5 SD (group A) ≥ –2.5 SD (group B) difference between A and B
BMD of the femoral neck [g/cm2] 0.673 0.783 P < 0.01
(0.562–1.003) (0.532–0.993)
T-score of the femoral neck –2.53 –1.64 P < 0.005
(–3.48; 0.200) (–3.73; 0.11)
BMD of ultradistal radius [g/cm2] 0.263 0.326 P < 0.0001
(0.195–0.449) (0.236–0.448)
T-score of ultradistal radius –3.48 –1.4 P < 0.000001
(–4.99; –2.52) (–2.40; 1.24)
BMD of proximal radius [g/cm2] 0.489 0.667 P < 0.0001
(0.390–0.746) (0.494–0.905)
T-score of proximal radius –2.98 –0.76 P < 0.00005
(–3.76; –1.78) (–1.88; 1.18)
BMD of spine [g/cm2] 0.847 0.887 P < 0.05
(0.596–1.104)  (0.753–1.349)
T-score of spine –2.94 –2.61 P < 0.05
(–5.03; 0.88) (–3.72; 1.24)
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Figure 1. Serum total PTH, 1–84 PTH (CAP) and 7–84 PTH (CIP) concentrations and CAP/CIP ratio in women with lower (T-score
< –2.5) and higher (T-score ≥ –2.5) BMD of the ultradistal radius. Values shown as median (range)
Rycina 1. Stężenie w surowicy całkowitego PTH, 1–84 PTH (CAP) i 7–84 PTH (CIP) oraz stosunek CAP/CIP u kobiet z niską (T-score
< –2,5) i wysoką (T-score >= –2,5) BMD części ultradystalnej kości promieniowej. Wartości podano jako medianę, w nawiasach
wartości minimalna i maksymalna
Results
The basal data of both groups are shown in Tables I
and II. As can be seen the patients in the two groups
did not differ with regard to anthropometric and bio-
chemical parameters. In patients with a low BMD of
the ultradistal part of the radius a significantly lower
BMD was noted than at other measurement sites.
There was no significant difference between the gro-
ups with regard to serum “total” PTH (p = 0.066) and
CIP concentrations, but serum CAP concentrations and
CAP/CIP ratios were significantly higher in patients with
low BMD of the ultradistal radius (Fig. 1). However, if
the patients were divided into subgroups according to
BMD of the spine or proximal radius, no significant dif-
ferences were found (data not shown). If a femoral neck
T-score of –2.5 was used as a division criterion, the sub-
groups with and without osteoporosis differed signifi-
cantly with regard to PTH and CAP levels (data not
shown), although these subgroups also differed signi-
ficantly with regard to body weight and BMI, making
the interpretation of results difficult.
Because of the relatively small number of patients
the whole group of 60 subjects was included in the
multivariate analysis. Only those variables that showed
a significant relationship in the univariate analysis were
assessed. In the multivariate analysis “total” PTH, CAP
and CIP respectively, showed an independent relation-
ship only with serum phosphate concentration (b = –0.34,
p = 0.041, b = –0.39, p = 0.0019 and b = –0.26, p = 0.046,
respectively). In the univariate analysis significant ne-
gative correlations of ultradistal radius and femoral neck
BMD and T-score with serum PTH and CAP concen-
trations were found (not shown). However, despite this,
in the multivariate analysis femoral neck BMD and
T-scores correlated independently only with the body
mass (b = 0.463, p=0.00019 and b = 0.472, p = 0.00014,
respectively). No independent correlation was shown
between the ultradistal radius BMD and any of the pa-
rameters examined.
Discussion
The two groups examined were comparable with re-
gard to age and anthropometric (Table I) and bioche-
mical parameters (Table II).
It is not surprising that the two groups, divided ac-
cording to their ultradistal radius T-scores, differ signi-
ficantly with regard to femoral neck, spine and proxi-
mal radius measurements. It should be mentioned, ho-
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wever, that for some of the patients the T-scores were
different in different sites. This situation is well docu-
mented [25], although it may cause some problems with
data interpretation. For this reason it was impossible to
stratify and compare the group under examination with
regard to BMD measurements for different sites. The
subjects were matched appropriately according to age
and weight if the ultradistal radius was used as a strati-
fication criterion, but they differed significantly with
regard to these parameters when BMD measurements
from other sites were used for this purpose.
The aim of the study was to assess the influence of
PTH subfractions on trabecular bone. It is known that
PTH acts physiologically not only on cortical bone, but
also, and even predominantly, on trabecular bone [9,
26]. Conversely, pathologically increased PTH secretion
(as in primary or secondary hyperparathyroidism) ma-
inly influences cortical bone [27]. In spite of the fact that
PTH may play a role in the pathogenesis of senile oste-
oporosis, PTH concentrations in these patients are not
above the normal range. In the population examined
the median PTH values were rather low in both groups
(Fig. 1), although they were slightly higher in patients
with low BMD. It is possible that in these patients chan-
ged pulsatile secretion patterns may be of importance,
although the data regarding pulsatile PTH secretion in
osteoporosis patients are scarce (in patients with secon-
dary hyperparathyroidism the amplitude and frequen-
cy of pulses increases as well as the basal secretion [13]).
Samuels et al. [28] showed that there is no difference in
the pulsatile patterns of PTH secretion of young and
postmenopausal women. Conversely, it has been shown
in a small population of patients that pulsatile PTH se-
cretion in postmenopausal osteoporosis is decreased
[29]. It is also known that pulsatile pharmacological
administration of 1-34 PTH causes a distinct increase in
trabecular bone (spine) BMD [8]. In our study it was
impossible for various reasons to investigate this issue,
and attention was paid to another pathogenetic aspect
of senile osteoporosis.
As far as we know, this is the first paper to assess the
concentration of PTH subfractions, the 1–84 and 7–84
peptides, specifically in subjects with decreased BMD
of the trabecular bone and in patients with osteoporo-
sis. As shown in Figure 1, the serum CAP concentration
and CAP/CIP ratio are significantly higher in subjects
with an ultradistal radius T-score lower than –2.5. The
difference in serum “total” PTH concentrations betwe-
en the two groups examined was of borderline signifi-
cance. Such results are not surprising. As the cyclase-
activating subfraction of PTH (CAP) causes an increase
in bone resorption, it could be responsible for the de-
creased BMD in such patients. In univariate analysis
significant negative correlations were found between
serum CAP concentrations as well as the CAP/CIP ratio
and the T-score of the ultradistal radius. Correlations
of borderline significance between CAP level and the
CAP/CIP ratio and ultradistal radius BMD were also
found (data not shown). It should be mentioned, ho-
wever, that the univariate correlations were not strong
and in the multivariate analysis these results were not
confirmed. As the number of patients was relatively
small, the multivariate analysis was performed on the
total group and not on the separate subgroups. Conse-
quently, this may have influenced the results. Additio-
nally, BMD is influenced by many genetic and environ-
mental factors and only some of these (e.g. body weight,
the only factor independently correlating with femoral
neck BMD) were included in the analysis. The absence
of many of these factors may of course be misleading.
The CAP/CIP ratio in the group examined was defi-
nitely higher than 1.0. In patients with chronic kidney
disease the mean CAP/CIP ratio is close to 1.0. In ap-
proximately half the ratio is lower and in the other half
it is higher, sometimes much higher [18]. Gao et al. [14]
have shown that in healthy subjects aged 18–62 years
its value is 1.7, which is similar to the mean value for
the whole group examined in this study, but lower than
the CAP/CIP ratio in the subgroup of patients with
a low ultradistal radius BMD. Comparison with such
a “historical control” is, of course, not really justified, but
the results seem reasonable. The lower BMD in subjects
with a higher CAP/CIP ratio may be caused by increased
bone resorption. There are no published data, however,
regarding the influence of the CAP/CIP ratio or PTH sub-
fractions on BMD or bone turnover in healthy subjects.
Of course, this study does not allow us to draw any
conclusions about a causal relationship between serum
CAP concentration or CAP/CIP ratio and low trabecu-
lar bone mass. It is only possible to state the presence of
an association between these parameters.
Conclusions
In conclusion, in elderly women, low bone mineral
density of the ultradistal radius is associated with a hi-
gher concentration of the cyclase-activating subfraction
of PTH (CAP) and a higher CAP/CIP ratio. However,
further research is needed before the question of whe-
ther this is a causal relationship can be answered.
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